Sugi Predict

Sugi Predict / Compounds / SCHEMBL10054151

SCHEMBL10054151

SCHEMBL10054151

COc1cccc(-c2nnc(C)o2)c1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 5/20 0.69
▸ KMT2A Q03164 2/20 0.69
▸ NPC1 O15118 8/20 0.67
▸ RAB9A P51151 8/20 0.67
▸ SMN1; SMN2 Q16637 6/20 0.67
▸ TP53 P04637 5/20 0.67
▸ HPGD P15428 4/20 0.67
▸ ALDH1A1 P00352 4/20 0.67
▸ MAPT P10636 3/20 0.67
▸ MEN1 O00255 1/20 0.67
▸ TDP1 Q9NUW8 3/20 0.61
▸ NPSR1 Q6W5P4 1/20 0.61
▸ NOTUM Q6P988 2/20 0.58
▸ CASP3 P42574 1/20 0.54
▸ SENP7 Q9BQF6 1/20 0.54
▸ NFKB1 P19838 2/20 0.54
▸ NFKB2 Q00653 2/20 0.54
▸ RELA Q04206 2/20 0.54
▸ GLA P06280 1/20 0.54
▸ HSD17B10 Q99714 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1181062 0.90 KDM4E (0.78) KDM4EKMT2ANPC1RAB9ASMN1; SMN2
SCHEMBL19685292 0.85 NPC1 (0.69) KDM4EKMT2ANPC1RAB9ASMN1; SMN2
SCHEMBL8111957 0.85 KDM4E (0.55) KDM4EKMT2ANPC1RAB9ASMN1; SMN2
SCHEMBL3250240 0.85 NPC1 (0.72) KDM4EKMT2ANPC1RAB9ASMN1; SMN2
SCHEMBL1186459 0.84 MAOB (0.51) KDM4EKMT2ANPC1RAB9ASMN1; SMN2
SCHEMBL12896087 0.83 PIM1 (0.52) KDM4EKMT2ANPC1RAB9ASMN1; SMN2
SCHEMBL1630232 0.83 KDM4E (0.56) KDM4EKMT2ANPC1RAB9ASMN1; SMN2
SCHEMBL3492286 0.83 GSK3B (0.65) KDM4EKMT2ANPC1RAB9ASMN1; SMN2
SCHEMBL21776863 0.82 KDM4E (0.68) KDM4EKMT2ANPC1RAB9ASMN1; SMN2
SCHEMBL27990907 0.82 KDM4E (0.68) KDM4EKMT2ANPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024092011-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2024-05-02 — — WO disclosed
WO-2023006097-A1 BIFUNCTIONAL CHIMERIC HETEROCYCLIC COMPOUND AND USE THEREOF AS ANDROGEN RECEPTOR DEGRADER 海创药业股份有限公司 2023-02-02 — — WO disclosed
US-9505749-B2 Quinazolinone compounds and derivatives thereof AMGEN INC. (US) 2016-11-29 — — US disclosed
US-9149465-B2 Isoxazolines as inhibitors of fatty acid amide hydrolase INFINITY PHARMACEUTICALS, INC. (US) 2015-10-06 — — US disclosed
US-20150225396-A1 Quinazolinone Compounds and Derivatives Thereof AMGEN INC. 2015-08-13 — — US disclosed
US-8927551-B2 Isoxazolines as inhibitors of fatty acid amide hydrolase INFINITY PHARMACEUTICALS, INC. (US) 2015-01-06 — — US disclosed
WO-2014036022-A1 QUINAZOLINONE COMPOUNDS AND DERIVATIVES THEREOF AMGEN INC. (US) 2014-03-06 — — WO disclosed
US-8124625-B2 enhancing the expression of apoAI; prevention or therapy of dislipidemia SHIONOGI & CO., LTD. (JP) 2012-02-28 — — US disclosed
US-8124625-B2 enhancing the expression of apoAI; prevention or therapy of dislipidemia SHIONOGI & CO., LTD. (JP) 2012-02-28 — — US disclosed
US-8106051-B2 4-Chloro-N-(4-tolyl)benzamide; to enhance the serum level of apoAI SHIONOGI & CO., LTD. (JP) 2012-01-31 — — US disclosed
US-8053445-B2 Utilities of olefin derivatives SHIONOGI & CO., LTD. (JP) 2011-11-08 — — US disclosed
US-8053445-B2 Utilities of olefin derivatives SHIONOGI & CO., LTD. (JP) 2011-11-08 — — US disclosed
US-20110028482-A1 ISOXAZOLINES AS INHIBITORS OF FATTY ACID AMIDE HYDROLASE INFINITY PHARMACEUTICALS, INC. (US) 2011-02-03 — — US disclosed
US-20110028478-A1 ISOXAZOLINES AS INHIBITORS OF FATTY ACID AMIDE HYDROLASE INFINITY PHARMACEUTICALS, INC. (US) 2011-02-03 — — US disclosed
US-20090036457-A1 Utilities of olefin derivatives YAMAMORI TERUO 2009-02-05 — — US disclosed
US-20090036457-A1 Utilities of olefin derivatives YAMAMORI TERUO 2009-02-05 — — US disclosed
US-7429593-B2 Utilities of amide compounds SHIONOGI & CO., LTD. (JP) 2008-09-30 — — US disclosed
US-7429593-B2 Utilities of amide compounds SHIONOGI & CO., LTD. (JP) 2008-09-30 — — US disclosed
US-20080221112-A1 4-Chloro-N-(4-tolyl)benzamide; to enhance the serum level of apoAI YAMAMORI TERUO 2008-09-11 — — US disclosed
US-20080221112-A1 4-Chloro-N-(4-tolyl)benzamide; to enhance the serum level of apoAI YAMAMORI TERUO 2008-09-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110028478-A1 ISOXAZOLINES AS INHIBITORS OF FATTY ACID AMIDE HYDROLASE FAAH, FAAH2, HRH2 KDM4E 1965/4885KMT2A 2280/4885NPC1 1678/4885
US-20080221112-A1 4-Chloro-N-(4-tolyl)benzamide; to enhance the serum level of apoAI APOL1, PON1, APOB KDM4E 3943/4885KMT2A 2362/4885NPC1 226/4885
US-20150225396-A1 Quinazolinone Compounds and Derivatives Thereof TNKS, TPI1, TNKS1BP1 KDM4E 603/4885KMT2A 2449/4885NPC1 3907/4885
US-20090036457-A1 Utilities of olefin derivatives APOL1, APOB, NR1H2 KDM4E 4647/4885KMT2A 3744/4885NPC1 48/4885
US-20110028482-A1 ISOXAZOLINES AS INHIBITORS OF FATTY ACID AMIDE HYDROLASE FAAH, FAAH2, HRH2 KDM4E 1965/4885KMT2A 2280/4885NPC1 1678/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.